STL Index for: Photodynamic Therapy

Peri-procedural measures in dermato-surgery depend on patient factors and procedure type. Standardized guidelines support healthcare providers in optimizing outcomes, preventing infection, and reducing recovery time. Research is needed to evaluate purpose-designed moisturizers for post-procedural application and improving patient outcomes.

The proper and suitable application of antibiotics is crucial in maintaining their effectiveness amidst growing antibiotic resistance. Nevertheless, it is essential for prescribing practitioners to have a heightened understanding of resistance causes and strategies to counteract them.

This article is a general overview of hair removal practices, which have evolved from utilizing waxes and blades, to advanced lasers and electrolysis, with further advancements still being studied

Oral nicotinamide is an affordable over-the-counter supplement with demonstrated benefit in the treatment of a range of skin conditions, most notably AK and NMSC.

A summary of the most comprehensive and up to date guideline for treating non-melanoma skin cancer in Canada. Background, primary prevention, actinic keratosis, managing basal cell carcinoma, and squamous cell carcinoma, are covered.

Hidradenitis suppurativa (HS) is a chronic disease of the follicular unit that often leads to marked impairment of quality of life. This article reviews various treatment modalities for HS including laser, surgery, retinoids, immunosuppression, biologics, and antibiotics.

Administration of antibiotics, often for prolonged periods, has become the standard of care for acne. The authors provide current evidence to suggest that dermatologists should consider a departure from standard operating procedure by curtailing, if not discontinuing, the routine and regular use of antibiotics for acne.

Device-based therapies are promising alternatives for the treatment of onychomycosis because they can mitigate some of the negative factors associated with treatment failure. This article reviews the case for laser and light based therapies, for the treatment of nail fungus.

A variety of novel therapeutic modalities have recently become available for patients with cutaneous T cell lymphoma (CTCL). Here, we offer a brief overview of these agents and discuss their place in the spectrum of current therapies for CTCL.

An actinic keratosis is a pre-malignant cutaneous lesion that frequently manifests in sun-exposed areas of the skin as a small, rough, scaly erythematous papule. Therapy choices are guided by efficacy, adverse effects, cosmetic results, and patient compliance.

Methyl aminolevulinate-hydrochloride cream (Metvix® [in Canada] and Metvixia® [in the US], Galderma) in combination with photodynamic therapy (PDT) provides an effective treatment option for actinic keratoses (AKs), superficial basal cell carcinoma (sBCC), and Bowen’s disease (BD).

Acne vulgaris can represent a therapeutic challenge in terms of managing ongoing symptoms and preventing scar formation. Dermatologists may now have viable new alternatives for treating all grades of acne severity that circumvent the negative side-effects associated with many conventional options.

Actinic keratoses (AKs) are premalignant inflammatory skin lesions with the potential to transform into squamous cell carcinoma (SCC). There are several treatment options available for patients presenting with multiple AKs. Imiquimod is believed to stimulate and enhance host immune responses locally against skin tumors and viral infections.

Photodynamic therapy has been used for several years for the treatment of actinic keratoses and prevention of invasive nonmelanoma cancers. Recently, increasing physician expertise with the topical sensitizers and light sources employed in PDT has led to expanded applications.

The role of photodynamic therapy (PDT) in the treatment of in situ neoplasias and tumors of the skin is steadily increasing. Its principles of photodynamic action include an intratumoral enriched photosensitizer and light activation.

Imiquimod (S-26308, R-837) (1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4 amine), an immune response modifier, was approved as a 5% cream (Aldara, 3M Pharmaceuticals) by the US FDA in February 1997, for the treatment of genital and perianal warts.

Although PDT remains an investigational treatment modality in dermatology, several important areas of development may ultimately lead to official and practical acceptance of PDT for the skin. Various uses of PDT are evaluated.